|
|||||
|
|
Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII |
|
| Authors: | I. Scharrer,& H. J. Ehrlich |
| Affiliation: | Center of Internal Medicine, University Hospital,. Frankfurt, Germany Baxter Hyland Immuno, Vienna, Austria. scharrer@em.uni-frankfurt.de |
| Abstract: | De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation. |
| Keywords: | blood coagulation factor inhibitors clinical trials factor VIII haemophilia A incidence recombinant proteins |